Sp960
DISCRIMINATION AND MICROAGGRESSIONS IN MEDICINE: UNDERSTAND BEING AN UPSTANDER AND A BYSTANDER
Date
May 8, 2023
Explore related products in the following collection:
Society: DDW
All symposia are 90-minute sessions, led by two moderators, with a varying number of invited talks. The session may include Q&A which can be included within each speaker’s total presentation time (2-3 minutes at the end) or as a separate block within the session. The session may also include a panel discussion with noted and/or additional speakers. Science type and topic will vary by the session sponsor.
All symposia are 90-minute sessions, led by two moderators, with a varying number of invited talks. The session may include Q&A which can be included within each speaker’s total presentation time (2-3 minutes at the end) or as a separate block within the session. The session may also include a panel discussion with noted and/or additional speakers. Science type and topic will vary by the session sponsor.
Presenter
Tracks
Related Products
THE ROLE OF ENTERIC GLIAL CELLS AND AQP1 IN THE AMELIORATING EFFECT OF ELECTROACUPUNCTURE IN A RODENT MODEL OF VISCERAL HYPERSENSITIVITY
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
PANEL DISCUSSION
SOCIETY: DDW
MULTIMODAL SINGLE CELL ANALYSES REVEAL PATHOGENIC FIBROBLASTS IN PERIANAL FISTULA
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
GLIAL CONNEXIN-43 HEMICHANNELS ARE CRITICAL DETERMINANTS OF GUT INFLAMMATION IN MOUSE POSTOPERATIVE ILEUS AND REACTIVE HUMAN ENTERIC GLIA
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
